SCHEMBL3874385

SCHEMBL3874385

CCC(NC(=O)[C@@H](N)CC(F)(F)Cc1ccccc1)C(=O)c1noc(C(C)(C)C)n1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRSS1 P07477 5/20 0.35
PRSS2 P07478 5/20 0.35
PRSS3 P35030 5/20 0.35
TPSAB1 Q15661 5/20 0.35
CTSC P53634 3/20 0.34
F2 P00734 1/20 0.33
PLG P00747 1/20 0.33
KLKB1 P03952 1/20 0.33
HDAC4 P56524 6/20 0.33
HDAC6 Q9UBN7 4/20 0.33
CTSK P43235 2/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CTSH P09668 1/20 0.32
CYP2D6 P10635 1/20 0.32
MME P08473 1/20 0.32
ACE P12821 1/20 0.32
CPA1 P15085 1/20 0.32
ACE2 Q9BYF1 1/20 0.32
HDAC1 Q13547 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3877226 0.86 SMYD3 (0.37) PRSS1PRSS2PRSS3TPSAB1CTSC
SCHEMBL3881029 0.85 DPP4 (0.33) HDAC4
SCHEMBL5814696 0.83 PRSS1 (0.33) PRSS1PRSS2PRSS3TPSAB1F2
SCHEMBL5396687 0.83 PRSS1 (0.34) PRSS1PRSS2PRSS3TPSAB1CTSC
SCHEMBL13937593 0.82 CTSS (0.46) CTSKCTSBCTSS
SCHEMBL3870371 0.79 HDAC1 (0.44) CTSCHDAC4HDAC6CTSKCYP1A2
SCHEMBL3871942 0.79 DGAT1 (0.35) CTSCCTSKCTSBCTSS
SCHEMBL3870467 0.78 MMP1 (0.43) CTSCKLKB1HDAC4HDAC6CTSK
SCHEMBL3869390 0.77 CTSK (0.36) CTSCCTSKCYP1A2CYP3A4CTSH
SCHEMBL3969452 0.75 OPRK1 (0.37) CTSCHDAC6CTSKCYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7482448-B2 Compounds and compositions as cathepsin inhibitors AVENTIS PHARMACEUTICALS INC. (US) 2009-01-27 US disclosed
US-20060189657-A1 Novel compounds and compositions as cathepsin inhibitors AVENTIS PHARMACEUTICALS INC. (US) 2006-08-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189657-A1 Novel compounds and compositions as cathepsin inhibitors CTSB, CTSS, CTSK PRSS1 32/4885PRSS2 34/4885PRSS3 29/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.